Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Inflammation Drug Reduces Chance of Pre-Term Birth

By Thomas Luke, The Lead South Australia | November 7, 2016

Anti-inflammatory drug could prevent premature birth. (Credit: Sara Neff, The Lead South Australia)

Researchers from the University of Adelaide in South Australia have found a drug that blocks certain inflammation pathways prevented early birth entirely in pregnant mice.

Lead researcher Professor Sarah Robertson, the director of the Robinson Research Institute, said that the drug (+)-naloxone could be used much earlier in a pregnancy than previous treatments, potentially before any symptoms had developed.

“Most people when they think of labor, they just think of contractions and then the baby’s born,” she said.

“We’re targeting steps that happen much higher in that cascade of events, things that are occurring a lot earlier and a lot further upstream in that pathway.

“We’d be looking at which women were at risk in the second trimester of pregnancy and then commencing treatment soon thereafter.”

While the trial focused on the use of (+)-naloxone as a drug for long-term use, Robertson said it would also be possible to use a higher dosage to delay a pregnancy in emergencies.

“There’s also a second use for women who come into a clinic, if they’re in sufficiently early stage labor, this drug will also have value as a kind of treatment.

Pre-term births occur due to inflammation responses in the mother’s body, caused by the immune system recognizing the fetus as foreign and rejecting the pregnancy.

The drug (+)-naloxone works by blocking a specific immunity receptor known as  Toll-Like receptor 4 (TLR4) which, while important to the immune system, causes a range of inflammation issues during pregnancy.

The research, published today in the Nature journal Scientific Reports, found a number of other birth issues including stillbirth, infant death and low weight could also be treated using (+)-naloxone.

“Often when we use those terms they sound like they’re all different things, but they’re actually more related than many people would guess,” Robertson said.

“So if you can tackle inflammation and assist the immune system to withstand that stress it has benefits for all of those different problems.”

Currently pre-term birth is the major cause of death for children under five, with more than 1.1 million deaths each year. Pre-term births make up 12% of all births globally.

Professor Robertson said that more research is still needed to determine if (+)-naloxone or similar drugs can safely be used for human pregnancies.

“It’s still at least five years before anyone would consider testing it with pregnancy in humans.

“All of this relates to being able to develop good diagnostics to give us a good handle on predicting who’s at risk early enough to get in there and use these interventions.”

The Robinson Research Institute brings together internationally renowned researchers in human reproduction, pregnancy and child health.

South Australia’s capital Adelaide has three long-standing public universities, Flinders University, University of South Australia and the University of Adelaide, each of which are consistently rated highly in the international higher education rankings.

(Source: The Lead)


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50